Publications

CRISPR-Cas9 genetic screen leads to the discovery of L-Moses, a KAT2B inhibitor that attenuates Tunicamycin-mediated neuronal cell death.

Authors: S Pavlou, S Foskolou, N Patikas, SF Field, EK Papachristou, CD Santos, AR E...

Research group: Proteomics

E-pub date: 9 Mar 2023

Journal name: Sci Rep

A large-scale retrospective study in metastatic breast cancer patients using circulating tumor DNA and machine learning to predict treatment outcome and progression-free survival

Authors: EJ Beddowes, M Ortega-Duran, S Karapanagiotis, A Martin, M Gao, R Masina, R...

Research group:

E-pub date: 8 Mar 2023

Journal name:

Preclinical PET Imaging of Tumor Cell Death following Therapy Using Gallium-68-Labeled C2Am.

Authors: F Bulat, F Hesse, B Attili, C Solanki, IA Mendichovszky, F Aigbirhio, FJ Le...

Research group:

E-pub date: 2 Mar 2023

Journal name: Cancers (Basel)

Direct visualization of transcription-replication conflicts reveals post-replicative DNA:RNA hybrids.

Authors: H Stoy, K Zwicky, D Kuster, KS Lang, J Krietsch, MP Crossley, JA Schmid, KA...

Research group: Crossley Group

E-pub date: 1 Mar 2023

Journal name: Nat Struct Mol Biol

p53 in senescence – it’s a marathon, not a sprint.

Authors: E Sheekey, M Narita

Research group: Narita Group

E-pub date: 1 Mar 2023

Journal name: FEBS J

Cellular senescence: beneficial, harmful, and highly complex.

Authors: DJ Baker, M Narita, P Muñoz-Cánoves

Research group: Narita Group

E-pub date: 1 Mar 2023

Journal name: FEBS J

High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial.

Authors: J van Dorp, C Pipinikas, BBM Suelmann, N Mehra, N van Dijk, G Marsico, ML v...

Research group:

E-pub date: 1 Mar 2023

Journal name: Nat Med

CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study.

Authors: E-Y Kang, A Weir, NS Meagher, K Farrington, GS Nelson, P Ghatage, C-H Lee, ...

Research group: Brenton Group

E-pub date: 1 Mar 2023

Journal name: Cancer

Filters

Research Groups

Core Facilities

Start date

End date

CRISPR-Cas9 genetic screen leads to the discovery of L-Moses, a KAT2B inhibitor that attenuates Tunicamycin-mediated neuronal cell death.

A large-scale retrospective study in metastatic breast cancer patients using circulating tumor DNA and machine learning to predict treatment outcome and progression-free survival

Preclinical PET Imaging of Tumor Cell Death following Therapy Using Gallium-68-Labeled C2Am.

Direct visualization of transcription-replication conflicts reveals post-replicative DNA:RNA hybrids.

p53 in senescence – it’s a marathon, not a sprint.

Cellular senescence: beneficial, harmful, and highly complex.

High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial.

CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study.

Themes

Filters

Research Groups

Core Facilities

Start date

End date

CRISPR-Cas9 genetic screen leads to the discovery of L-Moses, a KAT2B inhibitor that attenuates Tunicamycin-mediated neuronal cell death.

A large-scale retrospective study in metastatic breast cancer patients using circulating tumor DNA and machine learning to predict treatment outcome and progression-free survival

Preclinical PET Imaging of Tumor Cell Death following Therapy Using Gallium-68-Labeled C2Am.

Direct visualization of transcription-replication conflicts reveals post-replicative DNA:RNA hybrids.

p53 in senescence – it’s a marathon, not a sprint.

Cellular senescence: beneficial, harmful, and highly complex.

High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial.

CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study.